La importancia de la determinación del HER 2 en el cáncer gástrico avanzado: a propósito de un caso clínico

Advanced gastric cancer (AGC) is an entity that encompasses two distinct clinical situations: locally advancedunresectable gastric cancer and metastatic disease, with chemotherapy as the standard treatment. HER2overexpression can occur in 9% to 38% of the cases with this disease and has been the first predictivebiomarker used for trastuzumab-targeted therapy in patients with advanced gastric and gastroesophagealtumors. This article presents a patient with AGC and positive HER2 treated with conventional chemotherapyplus trastuzumab as targeted therapy with adequate clinical response.